The Association between Immediate Postpartum Etonogestrel Implants and Positive Postpartum Depression Screens in Adolescents and Young Adults

Drake, E; Grush, K; Sheeder, Jeanelle; Tocce, Kristina

doi:10.1016/j.jpag.2020.05.010

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even if some data showed a small increased risk of post-partum anti-depressant use among women using the ENG implant [180], in a recent retrospective study, Drake et al [181] showed that the postpartum depression rate was significantly lower for women initiating immediate postpartum implants compared to those choosing other methods (4.1% vs. 9.5%, p = 0.04) [181].…”

Section: Post-partum Implant Placementmentioning

confidence: 99%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Progestin-only contraceptive implants provide long-acting, highly effective reversible contraception. We searched the medical publications in PubMed, CENTRAL, and EMBASE for relevant articles on hormonal implants published in English between 1990 and 2021. Levonorgestrel (LNG) 6-capsule subdermal implants represented the first effective system approved for reversible contraception. The etonogestrel (ENG) single rod dispositive has been widely employed in clinical practice, since it is a highly effective and safe contraceptive method. Abnormal menstrual bleeding is a common ENG side effect, representing the main reason for its premature discontinuation. Emerging evidence demonstrated that it is possible to extend the use of the ENG implant beyond the three-year period for which it is approved. The ENG implant could be an effective and discrete alternative to the IUD in young girls, such as post-partum/post-abortion. Implants should be inserted by trained skilled clinicians who previously provide adequate counselling about their contraceptive effect, benefits, and any possible adverse events. More studies are needed to validate the extended use of the ENG implant for up to 5 years.

show abstract

Section: Post-partum Implant Placementmentioning

confidence: 99%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Although maternal and reproductive health research in Jordan has been adequately addressed (e.g., [1][2][3][4][5]), the connection between the risk of developing PPD and contraceptive use (hormonal vs. non-hormonal) has not, to our knowledge, been addressed. There are many important factors to consider with this topic, both locally and internally, such as the utilization of healthcare services [14], time to initiate antidepressants in postpartum women [15], gestational weight gain [16], and the history of psychiatric disorders [17]. Therefore, the risk of developing PPD could be due to how intrapartum and postpartum biopsychosocial needs are managed, as well as other personal and health-related factors that could contribute to an increased risk of developing PPD.…”

Section: Depressive Symptoms In Postpartum Womenmentioning

confidence: 99%

Predictors of Depressive Symptoms in Postpartum Women: The Role of Contraceptive Use, Type and Health-Related Factors

Hamdan-Mansour¹,

Alkhaldi²,

Awamleh³

et al. 2022

JMJ

View full text Add to dashboard Cite

Background: The postpartum period is critical for women due to significant bio-psychosocial changes and the consequences of delivery. Aims: The purpose of this study was to investigate the role of the use of contraceptives and other health-related factors in the risk of developing postpartum depression among women in Jordan. Materials and methods: A cross-sectional, descriptive-correlational design was used to recruit 803 women using a convenience sample technique from the central district of Jordan. Data were collected on depressive symptoms, contraceptive use and type, and pregnancy health-related factors. Results: Using binary logistic regression analysis, non-hormonal contraceptives and musculoskeletal pain were significant predictors (p<.05) of the risk of developing depressive symptoms in the sampled women (OR=4.1, 3.8; respectively). For the women in our sample, 24.9% (n=200) developed depressive symptoms. Most of those who felt depressed reported suffering from insomnia (50.0%] and baby blues (13.0%), while loss of appetite was reported by 33.0%. The analysis also showed that 51.0% (n=409) had used at least one method of contraception. Among those using contraceptive methods, 31.0% had only used hormonal contraceptives compared to 69.0% using non-hormonal forms. Conclusion: Non-hormonal contraceptive use and musculoskeletal pain were found to be significantly associated with the risk of developing postpartum depressive symptoms. Family and reproductive health professionals need to emphasize the bio-psychological aspects of health for pregnant and postpartum women.

show abstract